Advertisement
Articles
Advertisement

Focus on Funding 4/14/06

Fri, 04/14/2006 - 11:56am


GOVERNMENT FUNDING

Novavax Receives Funding for HIV/AIDS Vaccine Research
Novavax Inc., Malvern, Pa., announced additional funding of about $1 million from the National Institute of Allergy and Infectious Diseases to fund the third year of a four-and-a-half year program to develop a novel HIV/AIDS virus-like particle vaccine.
Full Article

NIH Provides $24M to Support Bioinformatics
The National Center for Research Resources, a part of the National Institutes of Health (NIH), will provide $24.29 million over five years to the University of California, Irvine, to continue supporting the Biomedical Informatics Research Network.
Full Article

CombiMatrix and Texas A&M Receive National Academies Grant
CombiMatrix Corp. Mukilteo, Wash., in collaboration with Texas A&M University, College Station, Texas, was awarded a National Academies Keck Futures Initiative grant to fund a method to increase the speed of hybridization in DNA microarray applications.
Full Article

PRIVATE FUNDING

Columbia University Receives $200M to Fund Science Center
Columbia University, New York, received $200 million to establish The Jerome L. Greene Science Center, the largest gift in the school’s history and the largest private gift received by any U.S. university to create a single facility.
Full Article

Gates Foundation Donates $75M for Pneumonia Research
The Bill & Melinda Gates Foundation awarded $75 million to PATH, Seattle, a nonprofit organization focusing on breaking the cycles of poor health, to create a new, inexpensive vaccine to fight pneumonia.
Full Article

Santaris Raises $48M
Santaris Pharma, Hørsholm, Denmark, which develops RNA antagonist drugs based on locked nucleic acid, completed a EUR 40M (US$48.3M) private investment round by an international syndicate of life science venture investors.
Full Article

Helicos Announces $40M in Funding
Helicos BioSciences, Cambridge, Mass., secured new investments totaling $40 million from a syndicate of venture capital firms, to support its development of "true single molecule sequencing" technologies and techniques.
Full Article

Hunter-Fleming Raises $27M in New Financing
Hunter-Fleming, Bristol, UK, completed a Series B round of GBP15.5 million (US$27 million) financing to continue the clinical development of three compounds to treat Alzheimer's disease, neuronal repair and spinal cord injury, and neuropathic pain.
Full Article

Proteon Therapeutics Announces $19M in Funding
Proteon Therapeutics Inc., Kansas City, Mo., raised $19 million in a Series A venture capital round to advance its therapeutics to dilate human veins and arteries for use in vascular surgery and angioplasty.
Full Article

Isis Receives $75M for Product Development
Isis Pharmaceuticals Inc., Carlsbad, Calif., raised $75 million in financing to further develop its cholesterol-lowering drug, ISIS 301012, and two novel diabetes drugs from its metabolic disease program through key development milestones.
Full Article

GRANTS AVAILABLE

CNS Therapy Development for Lysosomal Storage Disorders
Agency: National Institutes of Health
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This grant aims to solicit applications on lysosomal storage disorders to improve CNS treatment outcomes, enhancing delivery and targeting of cells, enzymes, drugs, and genes into the brain, and developing novel therapeutic modalities, such as implantable biocapsules.
Full Article

Testing Stem Cell Therapy in Mouse Models of Premature Aging
Agency: National Institute on Aging
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This grant opportunity seeks applications to test stem cell therapies in mouse models of accelerated aging.
Full Article

Grants for Alzheimer's Disease Drug Discovery
Agency: National Institute on Aging
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This announcement seeks applications to discover, develop, and for preclinical testing in cellular, tissue, and animal models of novel compounds to prevent and treat the cognitive impairment and behavioral symptoms associated with Alzheimer's disease.
Full Article

Collaborative Research in Stem Cell Biology
Agency: National Institute of Neurological Disorders and Stroke
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: The National Institute of Neurological Disorders and Stroke seeks applications to develop research projects to design, refine, and improve the use of stem cells for diagnostic or therapeutic applications to neurological disorders.
Full Article

Basic and Clinical Research on Rett Syndrome and MECP2
Agency: National Institutes of Health
Estimated Funding: $50,000
Due Date for Applications: Multiple dates, see Web site
Description: This announcement invites research grant applications aimed at understanding and/or treating Rett Syndrome, including developmental, neuroanatomical, molecular genetic, and pathophysiological research, therapy development projects, and clinical studies.
Full Article

Stem Cells and Cancer
Agency: National Cancer Institute
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This grant seeks to stimulate research on all aspects of stem cell biology, including research into the molecular and biochemical regulation of embryonic and adult stem cell behavior, and the most recent research on tumor stem cells.
Full Article

HIV Vaccine Research and Design Program
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant supports multi-project, multidisciplinary HIV/AIDS prophylactic vaccine-related studies including immunity to HIV/AIDS, increasing immunogenicity of HIV antigens, development or improvement of vaccine vectors, and improved animal model systems to address vaccine efficacy.
Full Article

Immunoregulation of Gastrointestinal Carcinogenesis
Agency: National Cancer Institute
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This grant announcement seeks researchers interested in investigating the roles of the mucosal immune system in inflammatory responses and/or the molecular mechanism(s) by which immunoregulatory cells dampen inflammation and decrease tumorigenesis.
Full Article

Etiology, Prevention, and Treatment of Hepatocellular Carcinoma
Agency: National Institutes of Health
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This announcement seeks grant applications to address the etiology of hepatocellular carcinoma and the development of animal models, novel preventive approaches, and therapeutic or diagnostic studies to establish reliable prognostic indicators for disease progression.
Full Article

Protein Biomarkers of Infection-Associated Cancers
Agency: National Cancer Institute
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This funding opportunity invites new research proposals to identify protein biomarkers for cancers where the etiology of the disease is due to infectious agents.
Full Article

Pilot Studies in Pancreatic Cancer
Agency: National Cancer Institute
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This funding opportunity intends to promote innovative research across multiple disciplines to better understand the biology, etiology, detection, prevention, and treatment of pancreatic cancer.
Full Article


Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading